Abstract
The spectacular marketing success of the selective cyclooxygenase 2 (COX-2) inhibitors is largely based on efficacy comparable with conventional non-steroidal anti-inflammatory drugs (NSAIDs) with vastly improved gastrointestinal safety. The additional key to the marketing success is the purity and simplicity of the message-that is, COX-1 inhibition causes the gastrointestinal side effects of NSAIDs (COX-1 dogma) while COX-2 blocking confers the therapeutic benefits (COX-2 dogma). Adherence to the COX dogmas with development of COX-2 selective agents has undoubtedly benefited many patients, but ironically their scientific basis is now seriously challenged by experimentation
| Original language | English |
|---|---|
| Pages (from-to) | 1376 - 1378 |
| Number of pages | 3 |
| Journal | Gut |
| Volume | 52 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 1 Sept 2003 |